Brett H. Pogostin

Mr. Brett H. Pogostin

Rice University Department of Bioengineering
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
TBTsvetelina H. Baryakova
Tsvetelina H. Baryakova
BPBrett H. Pogostin
Brett H. Pogostin
RLRobert Langer
Robert Langer
KMKevin J. McHugh
Kevin J. McHugh
Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.

25 January 2023 in Advanced Materials
Verified
Journal Article
Closed access
AFAdam C. Farsheed
Adam C. Farsheed
ATAdam J. Thomas
Adam J. Thomas
BPBrett H. Pogostin
Brett H. Pogostin
JHJeffrey D. Hartgerink
Jeffrey D. Hartgerink

23 January 2019 in Molecules
Verified
Journal Article
Open access
PDF file
BPBrett H. Pogostin
Brett H. Pogostin
Anders MalmendalAnders Malmendal
Anders Malmendal
CLCasey Londergan
Casey Londergan
KAKarin Akerfeldt
Karin Akerfeldt
Determining the pKa of key functional groups is critical to understanding the pH-dependent behavior of biological proteins and peptide-based biomaterials. Traditionally, 1H NMR spectroscopy has been used to determine the pKa of amino acids; however, for larger molecules and aggregating systems, this method can be practically impossible. Previous studies concluded that the C-D stretches in Raman are a useful alternative for determining the pKa of histidine residues. In this study, we report on the Raman application of the C2-D probe on histidine’s imidazole side chain to determining the pKa of histidine in a short peptide sequence. The pKa of the tripeptide was found via difference Raman spectroscopy to be 6.82, and this value was independently confirmed via 1H NMR spectroscopy on the same peptide. The C2-D probe was also compared to other Raman reporters of the protonation state of histidine and was determined to be more sensitive and reliable than other protonation-dependent signals. The C2-D Raman probe expands the tool box available to chemists interested in directly interrogating the pKa’s of histidine-containing peptide and protein systems.

10 September 2025 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
BPBrett H. Pogostin
Brett H. Pogostin
SWSamuel X. Wu
Samuel X. Wu
MSMichael J. Swierczynski
Michael J. Swierczynski
CPChristopher Pennington
Christopher Pennington
SLSi-Yang Li
Si-Yang Li
KMKevin J. McHugh
Kevin J. McHugh
Maintaining safe and potent drug levels in vivo is challenging. Multidomain peptides assemble into supramolecular hydrogels with a well-defined, highly porous nanostructure that makes them attractive for drug delivery. However, their ability to extend release is typically limited by rapid drug diffusion. Here, to overcome this challenge, we present self-assembling boronate ester release (SABER) multidomain peptides capable of engaging in dynamic covalent bonding with payloads containing boronic acids. As examples, we demonstrate that SABER hydrogels can prolong the release of boronic acid-containing small-molecule drugs and boronic acid-modified biologics such as insulin and antibodies. Pharmacokinetic studies reveal that SABER hydrogels extend the therapeutic effect of ganfeborole from days to weeks, preventing Mycobacterium tuberculosis growth compared with oral administration in an infection model. Similarly, SABER hydrogels extended insulin activity, maintaining normoglycemia for 6 days in diabetic mice after a single injection. These results suggest that SABER hydrogels present broad potential for clinical translation.

20 January 2021 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
DLDavid G. Leach
David G. Leach
NDNeeraja Dharmaraj
Neeraja Dharmaraj
TLTania L. Lopez-Silva
Tania L. Lopez-Silva
JVJose Rodriguez Venzor
Jose Rodriguez Venzor
BPBrett H. Pogostin
Brett H. Pogostin
SYSimon Young
Simon Young

24 October 2021 in Bioengineering
Verified
Journal Article
Open access
PDF file
BPBrett H. Pogostin
Brett H. Pogostin
KMKevin J. McHugh
Kevin J. McHugh
Future infectious disease outbreaks are inevitable; therefore, it is critical that we maximize our readiness for these events by preparing effective public health policies and healthcare innovations. Although we do not know the nature of future pathogens, antigen-agnostic platforms have the potential to be broadly useful in the rapid response to an emerging infection—particularly in the case of vaccines. During the current COVID-19 pandemic, recent advances in mRNA engineering have proven paramount in the rapid design and production of effective vaccines. Comparatively, however, the development of new adjuvants capable of enhancing vaccine efficacy has been lagging. Despite massive improvements in our understanding of immunology, fewer than ten adjuvants have been approved for human use in the century since the discovery of the first adjuvant. Modern adjuvants can improve vaccines against future pathogens by reducing cost, improving antigen immunogenicity, and increasing antigen stability. In this perspective, we survey the current state of adjuvant use, highlight potentially impactful preclinical adjuvants, and propose new measures to accelerate adjuvant safety testing and technology sharing to enable the use of “off-the-shelf” adjuvant platforms for rapid vaccine testing and deployment in the face of future pandemics.